Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Inclusion Criteria:

- A healthy male or female, 19 to 64 years of age (not having reached the 65th birthday)
at the time of study vaccination.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the
study vaccine(s) within 30 days preceding administration of study vaccine, or planned
use during the active phase of the study.

- Chronic administration of immunosuppressants or within six months prior to
administration of study vaccine.

- Planned administration/ administration of a vaccine not foreseen by the study protocol
within 30 days of administration of study vaccine (with the exception of an influenza
vaccine).

- Administration of a diphtheria-tetanus (Td) booster within previous five years.

- Administration of Tdap vaccine at any time prior to study entry. History of serious
allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria
toxoid or pertussis-containing vaccine or any component of the study vaccines.